Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week Low – Here’s What Happened

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) reached a new 52-week low on Thursday . The company traded as low as $13.68 and last traded at $13.72, with a volume of 111192 shares. The stock had previously closed at $14.11.

Analyst Upgrades and Downgrades

DYN has been the topic of a number of research reports. Baird R W raised Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of Dyne Therapeutics in a research note on Friday, January 10th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $45.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. Chardan Capital reaffirmed a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a research note on Friday, January 10th. Finally, Robert W. Baird assumed coverage on Dyne Therapeutics in a research note on Friday, December 13th. They issued an “outperform” rating and a $46.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $49.91.

Dyne Therapeutics Stock Performance

The stock has a 50 day moving average price of $24.65 and a 200 day moving average price of $32.90. The company has a market capitalization of $1.43 billion, a P/E ratio of -3.96 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Insiders Place Their Bets

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 782 shares of Dyne Therapeutics stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $33.10, for a total value of $25,884.20. Following the sale, the director now owns 15,962 shares of the company’s stock, valued at approximately $528,342.20. The trade was a 4.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Oxana Beskrovnaya sold 2,334 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $65,632.08. Following the completion of the sale, the insider now directly owns 201,685 shares in the company, valued at approximately $5,671,382.20. This trade represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,071 shares of company stock valued at $606,476. Company insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. State of New Jersey Common Pension Fund D purchased a new position in Dyne Therapeutics in the 3rd quarter worth approximately $1,588,000. Jennison Associates LLC grew its stake in Dyne Therapeutics by 1.5% in the 3rd quarter. Jennison Associates LLC now owns 1,346,952 shares of the company’s stock worth $48,383,000 after buying an additional 19,730 shares in the last quarter. Mutual of America Capital Management LLC purchased a new position in Dyne Therapeutics in the 2nd quarter worth approximately $1,724,000. RA Capital Management L.P. grew its stake in Dyne Therapeutics by 5.5% in the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock worth $229,211,000 after buying an additional 331,940 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Dyne Therapeutics by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company’s stock worth $66,802,000 after buying an additional 84,760 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.